From Dysbiosis to Therapy: The Role of Gut Microbiota-Derived Metabolites in IBD

Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic disorder of the gastrointestinal tract characterized by recurrent inflammation and dysregulated immune responses. Emerging evidence highlights the crucial role of gut microbiota and their metabolites in both the pathogenesis and potential treatment of IBD. This mini-review explores key microbial-derived compounds—including short-chain fatty acids (SCFAs), tryptophan metabolites, bile acids, and other bioactive molecules—that serve as mediators between host physiology and the intestinal microbial ecosystem. SCFAs such as butyrate, acetate, and propionate are essential for maintaining gut barrier integrity and immune homeostasis; however, their concentrations are often diminished in IBD patients. Similarly, tryptophan metabolism produces compounds like indole-3-acetic acid, which modulate gut immunity, though this pathway is frequently disrupted in disease states. Alterations in bile acid profiles also contribute to IBD pathophysiology by impacting receptors involved in metabolic and immune regulation. Moreover, imbalances in other microbial metabolites, including hydrogen sulfide, have been linked to exacerbated mucosal inflammation and epithelial damage. Therapeutic strategies aimed at restoring microbial metabolite balance are under active investigation. These include dietary interventions, SCFA supplementation, targeted probiotic formulations, bile acid receptor agonists, and fecal microbiota transplantation (FMT). This review further discusses the challenges of personalizing such interventions based on inter-individual variability in the microbiome, as well as the need for advanced metabolomic tools to better characterize these interactions in clinical contexts. In summary, deepening our understanding of gut microbiota-derived metabolites offers promising avenues for IBD therapies that go beyond symptom control, targeting underlying disease mechanisms at the microbial-host interface.